Drug Profile


Alternative Names: ALKS 33/olanzapine; ALKS 3831; Olanzapine/ALKS 33; Samidorphan/olanzapine

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Alkermes plc
  • Class Amides; Antipsychotics; Benzodiazepines; Oxazepines; Small molecules; Thiazepines
  • Mechanism of Action Dopamine D1 receptor antagonists; Dopamine D2 receptor antagonists; Opioid mu receptor antagonists; Serotonin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Schizophrenia

Most Recent Events

  • 01 May 2017 Alkermes completes enrolment in the ENLIGHTEN-1 trial for Schizophrenia in USA (PO) (NCT02634346)
  • 06 Mar 2017 Alkermes plans a phase III trial in Schizophrenia patients in USA (Alkermes plc 10-K, February 2017)
  • 01 Feb 2017 Alkermes completes a phase II trial for Schizophrenia with co-occurring alcohol abuse in USA, Bulgaria and Poland (NCT02161718)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top